CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinue production of Fluorognost HIV-1 IFA test kits routinely used for confirmation of HIV-1 antibody-reactive donations. Based on our current testing volume, CTS has sufficient HIV-1 IFA reagent inventory to continue performing this confirmatory test through the end of August 2019.
Check out the Communication page for the complete details on the updated IFA HIV-1 assay or by clicking the link: Communications
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
National Blood Donor Month has been observed in January since 1970, with the goal of increasing bloo...
Honor Your StaffCelebrate Lab Week, and honor yourself and your colleagues as a vital part of the la...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
On June 13, 2019, the new CTS Laboratory Information System was successfully implemented in Cha...